| Product Unit Size | Cost | Quantity | Stock |
|---|
CM346 may display anxiolytic activity, although it is early in developmental stages. It has also shown cardioprotective and neuroprotective activities. In a mouse model of Parkinson’s disease, treatment with CM346 was found to improve performance on the rotarod test.
| Cas No. | 173352-39-1 |
|---|---|
| Purity | ≥99% |
| Formula | C15H21N3O2S • HCl |
| Formula Wt. | 343.87 |
| IUPAC Name | 6-Ethoxy-2-{[2-(4-morpholinyl)ethyl]sulfanyl}-1H-benzimidazole hydrochloride (1:1) |
| Synonym | Obenoxazine, Afobazole, SM-346, Fabomotizole |
| Solubility | Soluble in water (1440 mg/ml at 20° C), ethanol, chloroform, and alcohol. Insoluble in ether. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Kadnikov I, Verboyava E, Voronkov D, et al. Deferred administration of afobazole induces sigma1R-dependent restoration of striatal dopamine content in a mouse model of Parkinson’s disease. Int J Mol Sci. 2020 Oct 15;21(20):7620. PMID: 33076300.
Kryzhanovskii S, Antipova T, Vititnova M, et al. Angiogenic affects of anxiolytic fabomotizole. Dokl Biochem Biophys. 2021 Mar;497(1):63-65. PMID: 33895918.
Kapitsa I, Kalinina A, Alymov A, et al. Afobazole alleviates cognitive rigidity in experimental model of autism spectrum disorders. Bull Exp Biol Med. 2019 Dec;168(2):238-241. PMID: 31776949.